HOUSTON,Texas-April1,2004 -Cell>Point L.L.C. completes clinical pilot study on ^99mTc-EC-Annexin V at The University of Texas M.D. Anderson Cancer Center. The study evaluated the use of  ^99m Tc-EC-Annexin V to assess tumor apoptosis (programmed cell death) in patients with primary breast cancer and to detect and image treatment related apoptosis in patients with primary breast cancer. The images produced in the study exceeded the company’s expectations. By using ^99mTc-EC-Annexin V, the oncologist will be able to detect cell death much more quickly than current practice.